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Abstract A high-affinity antiluminal uptake system for ß-
alanine was demonstrated in primary cultured bovine brain 
capillary endothelial cells (BCEC) for which K, is 66.9 μΜ. β-
alanine uptake was energy-, sodium- and chloride ion-dependent. 
ß-amino acids strongly inhibited the uptake, while a- and γ-
amino acids had a little or no inhibitory effect. In ATP-depleted 
cells, the uptake was stimulated by preloading ß-alanine or 
taurine but not by L-leucine. These results suggest that ß-alanine 
is actively transported across the antiluminal membrane of 
BCECs that is common to ß-amino acids. The system may 
function for the efflux from the brain to blood. 
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1. Introduction 
Beta (ß)-alanine is a neurotransmitter, the derivative of as-
partate, and the structural analog of major inhibitory neuro-
transmitters γ-aminobutyric acid (GABA) and glycine, and 
neuroactive sulfur amino acid taurine. The physiological im-
portance of high-afRnity uptake systems for neurotransmitter 
amino acids is a subject of intensive study [1,2]. The transport 
of ß-amino acids in Ehrlich cells has been studied principally 
by Christensen [3]. Some later studies showed that ß-alanine 
and taurine share a common transport system, the so-called ß-
amino acid transport system, in various tissues [4,5]. The 
study of transport mechanism of ß-alanine in brain was re-
stricted in neurons, astrocytes or synaptosomal membrane 
vesicles [6,7]. It has recently been clarified whether such a ß-
amino acid transport system functions at the blood-brain 
barrier (BBB). We have studied the transport characteristics 
of taurine at the BBB in vitro and in vivo [8]. Taurine trans-
port was dependent on Na + and Cl_ gradients and was in-
hibited by ß-amino acids. We performed the in vitro study as 
a model of blood-to-brain transport (uptake from luminal 
membrane side) and of brain-to-blood transport (uptake 
from antiluminal membrane side). It is interesting that the 
antiluminal transport of taurine by using primary cultured 
bovine brain capillary endothelial cells (BCEC) also showed 
an active system. We have also found that the luminal trans-
port of ß-alanine by BCECs was mediated by an active trans-
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port mechanism which required Na + and Cl_ [9]. Therefore, it 
is attractive to investigate the transport of ß-alanine across the 
brain to blood of BBB. 
Although brain endothelial cells morphologically do not 
show obvious polarity, biochemical polarity is well established 
[10,11]. Some evidence suggests that polarity also exists con-
cerning the transport of amino acids and glucose at the BBB 
[12-14]. It seems likely that the transport polarity of endothe-
lial cells is important to the BBB function. However, transport 
polarity and its physiological significance are difficult to study 
by in vivo techniques. Primary cultured monolayers of bovine 
BCECs offer the advantage for studies of the transendothelial 
transport of various substances [15-18]. Furthermore, it is 
expected that the monolayers of BCECs remains polarized 
because several membrane functions have been reported to 
localize in the manner that is consistent with the brain capil-
lary endothelial cells in vivo [8,12,19,20]. These features of the 
cultured cells enable us to study the polarized transport char-
acteristics at the antiluminal membrane. 
In this study, we have used an in vitro model to character-
ize the role of the endothelial component of the BBB in reg-
ulating ß-alanine delivery across the brain. The purpose of the 
present study is to elucidate the characteristics of the antilumi-
nal transcellular transport of ß-alanine at the BBB by using 
the primary cultures of BCECs. Findings from this study will 
contribute to a better understanding of brain-to-blood trans-
port of ß-amino acids and related ß-amino acid-mimetic drugs 
across the BBB. 
2. Materials and methods 
2.1. Materials 
[3-3H(N)]ß-Alanine (92.6 Ci/mmol) and [14C(U)]sucrose (4.03 mCi/ 
mmol) were purchased from New England Nuclear (Boston, MA). 
Horse serum was obtained from Gibco (Grand Island, NY). Rat 
tail collagen (type I) was from Collaborative Research Inc. (Bedford, 
MA), human fibronectin from Boehringer Mannheim GmbH (Mann-
heim, Germany), and bovine serum albumin (Fraction V) from Sigma 
Chemical Co. (St. Louis, MO). All other chemicals were commercial 
products of reagent grade. 
2.2. Isolation and culture of BCECs 
BCECs were isolated from cerebral gray matter of bovine brains by 
the method of Audus and Borchardt [21] with minor modifications. 
We have reported the details of the procedures for the preparation 
and the cell culture [22]. The isolated BCECs were stored at -100°C 
in culture medium containing 20% horse serum and 10% dimethylsulf-
oxide until use. Prior to seeding, the Transwell® polycarbonate mem-
branes (12 mm diameter, 12 μιη pore size, Costar, Cambridge, MA), 
were coated with rat tail collagen, sterilized in UV light, and coated 
with human fibronectin. Isolated BCECs were cultured at 37°C under 
95% air and 5% CO2. Transport experiments were performed when 
cells had reached confluence (in 10-12 days). These cultured cells were 
demonstrated to be endothelial cells by an immunostaining method 
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using von Willebrand Factor (Factor VIII related antigen, data not 
shown). 
2.3. Uptake experiments 
In order to measure antiluminal uptake, cultured BCECs were 
grown on Transwell® membranes. Cultured BCECs were washed 
3 times with 1 ml of Na+- and Cl~-free incubation solution (sucrose 
solution). Sucrose solution was consisted of 240 mM sucrose, 4 mM K 
gluconate, 2.8 mM CaS04, 1 mM MgSC<4, 10 mM D-glucose, 10 mM 
HEPES, and 0.1% bovine serum albumin, pH 7.4 at 37°C, 290 mOsm/ 
kg. Uptake was initiated by adding 1.5 ml of incubation solution to 
the outside (antiluminal side) containing [3H]ß-alanine (10 nM) and 
[14C]sucrose (50 μΜ), and adding 500 ul of sucrose solution to the 
inside (luminal side), minimizing the luminal-reuptake. Incubation 
solution was consisted of 141 mM NaCl, 4 mM KC1, 2.8 mM CaCl2, 
1 mM MgSC-4, 10 mM D-glucose, 10 mM HEPES and 0.1% bovine 
serum albumin, pH 7.4 at 37°C, 290 mOsm/kg. Moreover to minimize 
re-uptake from the luminal side, sucrose solution on the luminal side 
was replaced with fresh sucrose solution every 5 min. In order to 
terminate the transport reaction, cells were washed 3 times with 1 ml 
of the ice-cold incubation solution at the designated time. The washed 
cells were solubilized by incubating them with 300 μΐ of 1 M NaOH at 
room temperature for 60 min to quantitate the radioactivity asso-
ciated with the cells. After neutralization with 60 μΐ of 5 M HC1, 
the resultant sample was put into a plastic vial containing 4 ml of 
Clear-sol I (Nacalai Tesque Inc., Kyoto, Japan). The radioactivity was 
then measured by a liquid scintillation counter, LSC-1000 (Aloka Co. 
Ltd., Tokyo, Japan). Protein content in cultured cells was measured 
by the Lowry method [23] using bovine serum albumin as a standard. 
Net uptake was expressed as the cell-to-medium concentration (C/M) 
ratio, obtained by dividing the uptake amount by the initial concen-
tration (ul/mg protein), or as uptake rate (nmol/mg protein) after 
correction for extracellularly adsorbed ß-alanine, estimated from the 
apparent uptake of [14C]sucrose. 
In order to estimate the kinetic parameters of [3H]ß-alanine uptake 
in cultured monolayers of BCECs, the uptake rate (/, nmol/mg pro-
tein/30 min) was fitted to the following equation, by using the non-
linear least-squares regression analysis program, MULTI [24]: 
600 Γ 
/ = / m m 5 / ( ^ + S) (1) 
where J^^ is the maximum uptake rate for the carrier-mediated proc-
ess, S is a concentration of substrate, and Kt is a half-saturation 
concentration. 
The transport data were expressed as the mean ± SEM. The signifi-
cance of differences was evaluated by using Student's t test or 1-way 
analysis of variance. 
3. Results 
3.1. Time course of$-alanine uptake 
The time course of the antiluminal uptake of [3H] ß-alanine 
into cultured monolayers of BCECs is shown in Fig. 1. The 
value (expressed as C/M ratio) for [3H] ß-alanine was corrected 
for the extracellular space determined by using [14C]sucrose. 
Table 1 
Effect of temperature and metabolic inhibitors on the antiluminal 




(% of control)a 
Control 








0.1 ± 0.1* 
43.2 ± 9.0* 
29.9 ±12.9* 
38.3 ± 7.2* 
BCECs were preincubated for 20 min at 37°C with each metabolic 
inhibitor in the absence of D-glucose except ouabain. The uptake of 
[3H]ß-alanine (10 nM) was measured at 37°C or 4°C for 30 min in the 
presence or absence of metabolic inhibitor and D-glucose. 
"Each value represents the mean ± SEM of three to four experiments. 
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Fig. 1. Time courses of the antiluminal uptakes of [3H]ß-alanine. 
The uptake of [3H]ß-alanine (10 nM) was measured at 37°C. Each 
point represents the mean ± SEM of three to four experiments. 
When the SEM was small, it was included in the symbol. 
The C/M ratio of [14C]sucrose was 2 μΐ/mg protein (mean 
value of many experimental trials) and was almost constant 
within the experimental period. The data, corrected for the C/ 
M ratio for sucrose, show that the uptake of [3H]ß-alanine 
was linear over a 60 min incubation period. Based on this 
result, all subsequent experiments were conducted for 30 
min. The C/M ratio of [3H]ß-alanine uptake was determined 
to be 104.0±6.8 μ1/30 min/mg protein (meantSEM, n = 4), 
which was about 10-fold more than would be expected from 
the cellular volume, approximately 10 μΐ/mg protein [22]. Such 
an extensive accumulation of [3H]ß-alanine in BCECs was 
expected to be caused by a specific active transport across 
the membrane of BCECs. 
3.2. Concentration dependence of $-alanine uptake 
Fig. 2 shows the relationship between the initial antiluminal 
uptake rate and the concentration of ß-alanine (1-100 μΜ). 
The antiluminal uptake was suggested to be composed of a 
single saturable processes when analyzed by means of an Ea-
die-Hofstee plot. A nonlinear least-squares regression analysis 
of the results based on Eqn. 1 yielded values of the kinetic 
parameters, Kt and Jmax, of 66.9 ± 19.3 μΜ and 3.77 ± 0.66 
nmol/30 min/mg protein, respectively. 
3.3. Effect of temperature and metabolic inhibitors on the 
uptake of $-alanine 
The effects of temperature and metabolic inhibitors on the 
antiluminal uptake of [3H] ß-alanine are summarized in Table 
1. The uptake of [3H]ß-alanine at 4°C was less than 1% of the 
control value (37°C), showing a marked temperature depend-
ence. Addition of 1 mM DNP, an uncoupler of oxidative 
phosphorylation, or 10 mM sodium azide, a respiratory chain 
inhibitor, significantly reduced the uptake of [3H] ß-alanine at 
37°C by the antiluminal membrane. Moreover 0.5 mM oua-
bain, an inhibitor of Na+,K+-ATPase, reduced the antilu-
minal uptake of [3H]ß-alanine. 
3.4. Effect of ion replacement in the incubation solution on the 
uptake of $-alanine 
The effect of cations or anions on the antiluminal uptake of 
[3H]ß-alanine are summarized in Table 2. The substitution of 
Na + with choline or iV-methyl-D-glucamine in the presence of 
Cl_ completely abolished antiluminal uptake of [3H]ß-alanine. 
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Table 2 
Effect of sodium and chloride ions on the antiluminal uptake of 
[3H]ß-alanine 
3.0 r 














in the presence of Cl 
Uptake 





the presence of Na + 
Uptake 
(% of control)" 
100 ± 3.5 
32.4 ±11.4· 
10.8 ± 0.8· 
2.1 ± 0.6· 
The uptake of [3H]ß-alanine (!0 nM) was measured at 37°C for 30 
min. 
A: Cation indicates that Na+ in the incubation solution was replaced 
by other cations or sucrose. 
B: Anions indicate that Cl - in the incubation solution was replaced 
by other anions. 
" Each value represents the mean ± SEM of three to four experiments. 
•P<0.05 compared to control. 
In the presence of Na+ , [3H]ß-alanine uptake showed a 
marked anion-dependence. Replacing C l - with Br - or 
SCN - significantly reduced antiluminal uptake. Gluconate al-
most completely abolished the uptake of [3H]ß-alanine. 
Among the anions tested, the ability to stimulate the Na+-
dependent ß-alanine uptake was in the following order: 
C l - > B r - > SCN - »»gluconate-. Moreover, the replacement 
of NaCl with sucrose completely reduced the uptake of [3H]ß-
alanine. These results suggest that antiluminal uptake of ß-
alanine is dependent on Na + and C l - . 
3.5. Effect of structural analogs and various amino acids on the 
uptake of $-alanine 
The effects of various compounds on the antiluminal uptake 
of [3H]ß-alanine are summarized in Table 3. The uptake of 
[3H]ß-alanine was strongly inhibited by ß-amino acids (i.e., 
taurine and hypotaurine). Nipecotic acid, a ß-amino acid, 
possessing a ring structure, significantly inhibited the uptake 
of [3H]ß-alanine. An oc-amino acid (L-alanine) and γ-amino 
acid (GABA) also reduced the uptakes of [3H]ß-alanine. 
Furthermore, L-phenylalanine inhibited the antiluminal up-
take. In contrast, neither L-leucine nor L-glutamic acid inhib-
ited the uptake of [3H]ß-alanine. 
3.6. Countertransport effect on the uptake of $-alanine 
Countertransport by cultured cells that were ATP-depleted 
with 10 mM NaN3 is summarized in Table 4. The uptake of 
[3H]ß-alanine was significantly stimulated by the preloading of 
150 μΜ of unlabeled ß-alanine, or 60 μΜ or 90 μΜ taurine 
for 20 min. In contrast, preloading of 90 μΜ of L-leucine did 
not stimulate the antiluminal uptake of [3H]ß-alanine. 
4. Discussion 
For the first time, the characteristics of brain-to-blood (an-
tiluminal) transport of ß-alanine have been investigated by 
primary cultured bovine BCECs. Antiluminal uptake of ß-
100 
Concentration (μΜ) 
Fig. 2. Concentration dependence of the antiluminal uptake of 
[3H]ß-alanine. Initial uptake rates at various concentrations of ß-ala-
nine (1-100 μΜ) were measured at 37°C for 30 min. Each point 
represents the mean ± SEM of three to four experiments. When the 
SEM was small, it was included in the symbol. The solid line repre-
sents saturable uptake rate generated from Eqn. 1, using the MUL-
TI fitted parameters. Inset: Eadie-Hofstee plots of [3H]ß-alanine up-
take. 
alanine is temperature- and metabolic energy-dependent (Ta-
ble 1). The sensitivity to metabolic inhibitors suggested that 
the antiluminal passage of ß-alanine across BCECs was de-
pendent to some degree on the metabolic status of the cells. 
Na + -dependent ß-alanine uptake requires anion; especially, 
C l - is the most preferred among the tested anions (Table 
2). Further, the antiluminal uptake of ß-alanine consisted of 
a single saturable process (Fig. 2). In our previous study, the 
metabolite of taurine was not observed during 30 min incuba-
tion by BCECs (37CC) [8]. Similarly, we assumed that the 
metabolism of ß-alanine was negligible in the present study. 
Accordingly, the antiluminal uptake of ß-alanine was ascribed 
to the transport. It was demonstrated that [3H]ß-alanine is 
actively transported by a carrier-mediated mechanism from 
antiluminal side, consuming energy supplied by Na + and 
C l - gradients, as similarly observed for the luminal transport 
of ß-alanine [9] and antiluminal transport of taurine by 
BCECs [8]. At this point of view, the antiluminal transport 
of ß-alanine by BCECs has similar characteristics compared 
with the luminal transport [9]. 
Table 3 
Effect of amino acids and structural analogs on the antiluminal up-




























(% of control)" 
100 ± 3.5 
6.1 ± 0.3· 
5.5 ± 0.3· 
66.7 ± 5.9* 
58.3 ± 4.2· 
82.9 ± 6.0· 
32.4 ± 2.9* 
26.4 ± 2.2· 
41.0± 4.6* 
66.5 ± 9.3* 
90.9 ± 5.6 
100.9 ±11.3 
The uptake of [3H]ß-alanine (10 nM) was measured at 37°C for 30 
min in the presence of each compound. 
"Each value represents the mean ± SEM of three to four experiments. 
"P < 0.05 compared to control. 
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Recent studies have investigated whether taurine and ß-ala-
nine share a common carrier. Most of these studies concluded 
that taurine and ß-alanine are transported via the common 
transporter specific to ß-amino acids [4,5,25]. In neurons and 
astrocytes [6], and cultured glioma cells [26], ß-alanine com-
petitively interacts with the transport system for taurine. In 
contrast, Breckenbridge et al. [27] claimed that taurine was an 
ineffective inhibitor of ß-alanine transport by brain slices. 
Furthermore, the ileal ß-alanine transport system is not iden-
tical with that for taurine, since L-leucine was a high-affinity 
inhibitor of ß-alanine transport, but had no effect on taurine 
transport [28]. We assessed the inhibitory effect of ß-amino 
acid analogs and other amino acids on the transport of ß-
alanine by BCECs to address these contradictory findings. 
As seen in Table 3, [3H]ß-alanine uptake by BCECs was not 
inhibited by 5 mM L-leucine, being consistent with the fact 
that taurine uptake by antiluminal membrane of BCECs was 
not inhibited by 5 mM L-leucine [8]. This result indicates the 
ß-alanine transport system is probably different between ileum 
and BCECs. ß-amino acids such as taurine and hypotaurine, 
and structurally analogous compounds, significantly inhibited 
the uptake of ß-alanine (Table 3). This indicates that ß-ala-
nine transport is highly selective for ß-amino acids. Further-
more, countertransport of [3H]ß-alanine was observed by pre-
loading unlabeled ß-alanine or taurine (Table 4). These 
observations suggest that the affinity for the ß-amino acid 
transporter depends on the number of carbon atoms between 
the positive and negative charges, as suggested previously for 
taurine transport across the BBB [8]. 
Betz and Goldstein [10] concluded that small neutral amino 
acid transport system (A-system) is located on the antiluminal 
side of the isolated brain capillaries. However, substrates may 
enter endothelial cells through both membranes simulta-
neously in the isolated brain capillary. Asymmetrical trans-
port of ß-alanine by cultured cells is not known. In the present 
study, L-phenylalanine significantly inhibited the antiluminal 
ß-alanine transport (Table 3). On the contrary, luminal trans-
port of ß-alanine was not inhibited by L-phenylalanine [9]. L-
Phenylalanine is exclusively transported via the Na+-inde-
pendent L-system in various tissues [29]. However, it is un-
likely that ß-alanine is partly transported by the L-system 
because the antiluminal transport of ß-alanine was completely 
diminished in Na+-free condition (Table 2A). Since the excess 
concentration of phenylalanine (5 mM) was used to inhibit 
uptake of ß-alanine, it may not be the catabohc effect of 
Table 4 
Countertransport effect on the antiluminal uptake of [3H]ß-alanine 














(% of control)3 
100.0 ± 6.1 
207.3 ±34.8' 
168.8 ± 9.3' 
175.2 ±11.9' 
124.5 ±10.8 
BCECs were preincubated for 20 min with 10 mM NaN3 in the 
absence of D-glucose and with each compound. The uptake of 
[3H]ß-alanine (10 nM) was measured at 37°C for 30 min with 10 
mM NaN3 in the absence of D-glucose. The designated concentration 
in the table was non-radioactive ß-amino acids. 
Each value represents the mean ± SEM of four experiments. 
*P<0.05 compared to control. 
/. Komura et allFEBS Utters 4M (1997) 131-135 
phenylalanine. The important point with respect to the inhib-
itory effect by phenylalanine occurred only at the antiluminal 
membrane. The kinetic parameters of luminal side which we 
had obtained previously were At = 25.3 ± 2.5 (μΜ) and 
/max = 6.90 ± 0.48 (nmol/30 min/mg of protein) [9]. The anti-
luminal kinetic parameters were estimated to be 
Kt = 66.9 ± 19.3 (uM) and /m a x = 3.77 ± 0.66 (nmol/30 min/mg 
of protein) in the present study. Therefore, the transport ef-
ficiencies estimated by the values of Jmax/Kt (ml/30 min/mg 
protein) indicate that ß-alanine is transported more efficiently 
in the luminal (0.27) [9] than the antiluminal (0.06) mem-
branes. Based on our studies, the features of ß-alanine trans-
port across BCECs differs between the luminal and antilumi-
nal sides, seemingly due to one or more factors. For instance, 
one factor was the differing energy requirements of individual 
carriers. Another factor was significant differences in the bi-
directional ß-alanine transport where an apparent existence of 
unequal numbers of carriers on luminal and antiluminal sur-
faces of BCECs could have resulted in different efficiency of 
the systems. These findings suggest the functional polarity of 
cultured bovine BCECs. 
In summary, we have demonstrated the polar, saturable, 
Na+- and Cl_-dependent and active transport system for ß-
alanine at the antiluminal membrane of primary cultured 
BCECs. Furthermore, it was also shown that ß-alanine is 
transported by taurine-sensitive ß-alanine carrier system at 
the BBB. 
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